Oncotelic Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Oncotelic Therapeutics, Inc. (OTLC) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $0.05 per share for the 12-month period ending 2022-12-31, per its 10-K/A filed 2023-04-20.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2023-04-20
- Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $0.23, a 36.11% decline year-over-year.
- Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-03-31 was $0.36, a 111.76% increase year-over-year.
- Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-03-31 was $0.17.
- Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $0.05, a 70.59% decline from fiscal 2021.
- Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $0.17, a 22.73% decline from fiscal 2020.
- Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $0.22, a 15.79% increase from fiscal 2019.
- Oncotelic Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2019 was $0.19, a 18.75% increase from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.05 10-K/A · filed 2023-04-20 | |||
| 2022-09-30 | $0.07 10-Q · filed 2022-11-18 | |||
| 2022-06-30 | $0.17 10-Q · filed 2022-08-22 | |||
| 2022-03-31 | $0.23 10-Q · filed 2022-05-23 | |||
| 2021-12-31 | $0.17 10-K · filed 2022-04-15 | |||
| 2021-09-30 | $0.14 10-Q · filed 2021-11-22 | |||
| 2021-06-30 | $0.22 10-Q · filed 2021-08-20 | |||
| 2021-03-31 | $0.36 10-Q · filed 2021-05-24 | |||
| 2020-12-31 | $0.22 10-K · filed 2022-04-15 | |||
| 2020-09-30 | $0.18 10-Q · filed 2020-11-16 | |||
| 2020-06-30 | $0.19 10-Q · filed 2020-08-14 | |||
| 2020-03-31 | $0.17 10-Q · filed 2020-06-29 | |||
| 2019-12-31 | $0.19 10-K · filed 2021-04-15 | |||
| 2019-09-30 | $0.18 10-Q · filed 2019-11-19 | |||
| 2019-06-30 | $0.18 10-Q · filed 2019-08-19 | |||
| 2018-12-31 | $0.16 10-K · filed 2019-04-10 | |||
| 2017-12-31 | $0.34 10-K · filed 2019-04-10 | |||
| 2016-12-31 | $0.51 10-K · filed 2018-04-17 | |||
| 2015-12-31 | $1.05 10-K · filed 2017-03-30 | |||
| 2014-12-31 | $1.87 10-K · filed 2016-03-25 | |||
| 2013-12-31 | $2.77 10-K · filed 2015-03-30 | |||
| 2012-12-31 | $6.94 10-K · filed 2015-03-30 | |||
| 2011-12-31 | $7.42 10-K · filed 2014-03-20 | |||
| 2010-12-31 | $108.96 10-K · filed 2013-03-15 |